Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield. Targeting microbiome is a key.
Vous n'êtes pas connecté
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 17/08/2024 14:16
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukaemia, the approach has yet to realise its potential against paediatric solid tumours. Scientists at St. Jude Children’s Research Hospital have identified a way to improve CAR T–cell homing – a T cell’s ability [...]
Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield. Targeting microbiome is a key.
Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles...
Just before the pandemic took center stage in 2020, scientists at a T cell memory conference convened to discuss a less than traditional topic:...
Just before the pandemic took center stage in 2020, scientists at a T cell memory conference convened to discuss a less than traditional topic:...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this...
Scientists at the Massachusetts Institute of Technology (MIT) have discovered a method to restore lost strength to aging immune systems by using mRNA...
Creative Biolabs focuses on the research and application of exosomes derived from stem cells, leveraging a systematic technology platform to help...
Creative Biolabs focuses on the research and application of exosomes derived from stem cells, leveraging a systematic technology platform to help...
Up to GBP0.00 per year: Immunocore Holdings PLC: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company...
Up to GBP0.00 per year: Immunocore Holdings PLC: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company...